Moteur de recherche d’entreprises européennes
Financement de l’UE (11 M €) : Le diagnostic NGS en oncologie du 21e siècle : le meilleur, pour tous, à tout moment Hor01/01/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Le diagnostic NGS en oncologie du 21e siècle : le meilleur, pour tous, à tout moment
oncNGS consortium challenges the market to research and develop novel affordable solutions to provide the best NGS tests, for all solid tumours / lymphomas patients. The challenge will consist in providing: (1) efficient molecular DNA/RNA profiling of tumour-derived material in liquid biopsies by means of (2) pan-cancer tumour marker analysis kit including NGS analysis integrated with (3) an ICT decision support system including analytical test interpretation and reporting. Thanks to the provided solutions, oncNGS consortium will be able to address their common identified unmet medical needs: (1) Establishment of valuable common tumour profiling strategy allowing to provide equal access to innovative medicines to all; (2) Outcome research analysis after treatments with targeted therapies as diverse testing leads to lowering the pooling capacity of obtained results, needed to obtain large enough sample numbers to perform statistics analyses; (3) Application of such essential testing to all patients, breaking down current unacceptable inequities due to the high costs of current diagnostics tests. oncNGS is a strong consortium composed by eight buyers from five member states (SC and IJB from Belgium, IC and HCL from France, HC and LMU from Germany, ACC from Italy and ICO from Spain) supported by six entities with wide experience in their fields (AQuAS from Spain is expert in precommercial procurement, BCR from Belgium and INCa from France are experts in cancer control, IBSAL and VHIO are experienced in biomedical research in the field of haematologic malignancies and DCP is experts in intellectual property rights and freedom to operate analysis) oncNGS consortium will challenge the market launching a pre-commercial procurement procedure, a competitive process enabling the buyers to compare the developments carried out by the contracted suppliers through three phases: solution design, prototyping and clinical validation of a limited set of R&D supplies.
https://cordis.europa.eu/project/id/874467
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.